press enter »
placeholder
placeholder

Pfizer's atopic dermatitis treatment meets goals in late-stage study

Pfizer's atopic dermatitis treatment meets goals in late-stage study

(Reuters) - Pfizer Inc’s new atopic dermatitis treatment met the main goals in a late-stage study that tested the drug in patients aged 12 and older with moderate to severe forms of the disease, the drugmaker said on Wednesday. Abrocitinib, which belongs to a class of drugs known as JAK inhibitors, which block inflammation-causing enzymes, known as

Pfizer's dermatitis treatment meets main goals of late-stage study

Pfizer's dermatitis treatment meets main goals of late-stage study

(Reuters) - Pfizer Inc’s dermatitis treatment met the main goals in a late-study, testing the drug in patients aged 12 and older with moderate to severe form of the disease, the drugmaker said on Wednesday. The study tested two doses of the drug, abrocitinib, in 387 patients with atopic dermatitis, the company said. Atopic dermatitis is a chronic skin